Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Krystal Biotech (KRYS) Stock Price & Analysis

734 Followers

KRYS Stock Chart & Stats

$308.81$2.31(0.75%)
At close: 4:00 PM EST
$300$325$350Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$303.59 - $311.05
52-Week Range
$198.02 - $382.54
Previous Close
$306.50
Volume
N/A
Average Volume (3M)
315.23K
Market Cap
$9.08B
Enterprise Value
$9.35B
Total Cash (Recent Filing)
$911.85M
Total Debt (Recent Filing)
$8.59M
Price to Earnings (P/E)
40.3
Beta
0.55
Next Earnings
Mar 01, 2027 (Est.)
EPS Estimate
2.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

VYJUVEK Commercial Momentum

Strong VYJUVEK growth and cumulative revenue demonstrate meaningful patient treatment and physician adoption. Continued reimbursement approvals, prescriber additions, and utilization can support durable commercial expansion and reinforce the product’s position in its rare-disease market.

Strong Cash Generation And Liquidity

High operating and free cash flow, together with substantial liquidity, gives Krystal financial flexibility to fund clinical development, international launches, and commercial infrastructure without relying heavily on debt. Strong cash conversion also supports the quality and durability of reported earnings.

International And Pipeline Expansion

Progress across international market access and several HSV-1-based programs broadens Krystal’s future growth opportunities beyond current US sales. Additional geographic launches and potential new indications could diversify revenue and extend the platform’s commercial runway over time.

Bears Say

Gross-margin Pressure Overseas

The lower gross margin shows that geographic expansion can initially dilute product economics when manufacturing improvements are not yet applied across regions. If international sales become a larger revenue share before optimization, this mix effect could constrain margin expansion.

Clinical Development Delays

Delayed clinical readouts extend the time before pipeline programs can support regulatory filings or commercial revenue. Longer development timelines also defer potential diversification from VYJUVEK and require continued investment while outcomes remain dependent on future trial execution.

Historical Earnings And Cash-flow Volatility

The recent profitability inflection is encouraging, but prior losses and negative cash flow show that earnings power has not yet been tested across a long operating history. Sustaining results therefore depends on continued VYJUVEK commercial momentum and successful execution.

Krystal Biotech News

KRYS FAQ

What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $198.02 and its highest was $382.54 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $9.08B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s next earnings report is estimated for Mar 01, 2027 (not yet confirmed), which is in 109 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Nov 02, 2026. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.789 by $0.261.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 2.04.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,633,472 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $2.05 in its last earnings report, beating expectations of $1.789. Following the earnings report the stock price went down -10.951%.
Which hedge fund is a major shareholder of Krystal Biotech?
Hedge funds hold Krystal Biotech shares: the largest hedge-fund position in Krystal Biotech is 71,885,605 shares, and hedge funds increased their holdings by 238.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology